Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05588388 · ClinicalTrials.gov registry record · Phase 2

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

A Phase 2 study of Liver Metastases and Extensive-stage Small-cell Lung Cancer, sponsored by Kamya Sankar.

Recruiting
Registry status
Phase 2
Development phase
39
Enrollment target
3
Study locations

NCT05588388 is a Phase 2 study of Liver Metastases and Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Kamya Sankar. The registered enrollment target is 39 participants, below the 67-participant average among 27 other Liver Metastases trials with a reported enrollment target (42% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05588388, a Phase 2 study of Liver Metastases and Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Kamya Sankar.

RECRUITING
Registry status
Phase 2
Development phase
39 participants
Enrollment target
3
Study locations

Study Summary

This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: * In patients with ES-SCLC with liver metastases, can bevacizumab in combination with atezolizumab and chemotherapy prolong the length of time that the cancer does not progress? * Is bevacizumab safe and tolerable when combined with atezolizumab and chemotherapy in patients with ES-SCLC and liver metastases? The study treatment includes two phases: * Induction phase: bevacizumab will be administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles. * Maintenance: atezolizumab and bevacizumab will be administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression. Participants will undergo blood tests every 3 weeks and tumor assessments every 6 weeks.

Conditions Studied

Liver Metastases Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Bevacizumab

Study Locations (3)

Michigan

  • V.A. Ann Arbor Healthcare System - Ann Arbor
  • University of Michigan - Ann Arbor

California

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2024-08-11
Est. Completion 2027-12-28
Phase Phase 2

Sponsor

Kamya Sankar

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05588388

The ClinicalTrials.gov registry entry for NCT05588388 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 27 other Liver Metastases trials with a reported enrollment target (42% lower). The listed sponsor is Kamya Sankar, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Liver Metastases appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab is the first listed.

NCT05588388 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Michigan, California.

Frequently Asked Questions

What is clinical trial NCT05588388 about?

NCT05588388 is a clinical study titled "Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases". This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: ...

What is the current status of trial NCT05588388?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-08-11. Estimated completion is 2027-12-28.

What conditions does trial NCT05588388 study?

This clinical trial studies the following conditions: Liver Metastases, Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT05588388?

The interventions under investigation include: Bevacizumab (DRUG).

Who is sponsoring clinical trial NCT05588388?

This trial is sponsored by Kamya Sankar, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05588388 being conducted?

This trial has 3 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Metastases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Metastases

All registered trials for this condition

Extensive-stage Small-cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.